William Blair
About William Blair
William Blair is a global financial services firm specializing in investment banking, investment management, and private wealth management. The firm provides advisory services, strategies, and solutions to meet clients’ evolving needs across markets. It emphasizes thought leadership and research through its Think/Insights channels, delivering market perspectives and investment ideas to institutional, corporate, and private clients. Headquartered in the United States, William Blair operates with a multinational footprint and a focus on client-centric financial guidance.
Recent News
5 FDA Decisions to Watch in the First Quarter of 2026
Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
FDA Grants First Gene‑Therapy Approval for Rare Pediatric Immune Disorder LAD‑I
BMS Beats Again Despite Eliquis and Cobenfy Disappointments
Cognizant Sets Aside $270 Million For Layoffs In ‘Project Leap’ AI Operating Model Plan
Biogen Is Celebrating A First In Alzheimer's Disease. But Investors Are Leery.
How Non-Payments Became Big Business at Visa and Mastercard
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
What FIS Has Planned After the Global Payment Deals
The U.S. Inflation Problem Is Getting Worse
Birkenstock CEO Oliver Reichert Says He’s Confident of the Future
Asset Allocation Still Dominates Outcomes as Investors Navigate New Inflation Era, Says William Blair
Barclays Reiterates Overweight on BridgeBio Stock, Cites Attruby Strength
First Trump, Now Mamdani; Politicians Stepping Into Payments
William Blair to Buy Inner Circle, Bolstering Sports Dealmaking
Pentagon Seeks $2.3 Billion for Maven AI Battlefield System
William Blair Downgrades Adobe (ADBE) to Market Perform, Lowers PT
VCs Redirect Billions to Biotech as Hedge Against AI Bubble, PitchBook Reports
Broadtree Partners Closes $240 Million Multi‑Asset Continuation Fund
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
Arxis Prices Upsized $1.13 B IPO, Goldman, Morgan Stanley Lead Syndicate
Boehringer, Zealand’s Obesity Drug ‘More Akin’ to Novo’s Wegovy in Phase 3
Circle’s USDC Keeps Climbing; William Blair Reiterates Outperform After 3Q Results
Equifax CFO John Gamble to Lead Fireside Chats at Investor Conferences in May-June
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study
5 Questions Facing Biopharma in 2026
William Blair Seeks Expertise via Inner Circle Sports Acquisition Amid M&A Boom
GPs Increasingly Step up CV Alignment with Cross-Fund Commitments
Axsome Hits Record High On Alzheimer's Agitation Approval
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
Research Analysts Set Expectations for CSL FY2027 Earnings
Colliers Buys Ayesa, Which Bought ADP Just 12 Months Ago
Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations
Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study
William Blair to Acquire Inner Circle Sports
Cardiff Craters Amid Executive Exits, Mixed Mid-Stage Data
Amex CEO: 10% Rate Cap Would Create 'Downward Spiral'
CBRE’s Data Center Boom Fuels 19% Revenue Rise, Signals CRE Shift
Sarepta Saga Has 'Gone on Too Long' As Competitors Catch Up
AEVEX Corp Prices IPO at $20 a Share, Targets $336 Million in NYSE Debut
FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program
Pizza Hut Relaunches Huts Rewards
The IPO Buzz: Suja Life Prices IPO at $21 – Low End – Set for NASDAQ Debut Today
Basalt to Acquire Track Maintenance Plant Leasing Company RELAM
Mattress Firm Parent Somnigroup to Buy One of Its Suppliers for $2.5B
Visa Doles Out Stablecoin Advice
Real Estate Stock Prices Have Taken a Big Hit in the Past Year